CADL Stock Summary and Trading Ideas (Candel Therapeutics | NASDAQ:CADL)

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.

As of August 5, 2026, CADL stock price climbed to $10.68 with 126,879 million shares trading.

CADL has a beta of 0.82, meaning it tends to be less sensitive to market movements. CADL has a correlation of 0.02 to the broad based SPY ETF.

CADL has a market cap of $782.28 million. This is considered a Small Cap stock.

In the last 3 years, CADL traded as high as $14.60 and as low as $.66.

The top ETF exchange traded funds that CADL belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

CADL has outperformed the market in the last year with a price return of +69.3% while the SPY ETF gained +24.1%. CADL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +41.8% and +4.5%, respectively, while the SPY returned +8.4% and +3.7%, respectively.

CADL support price is $10.09 and resistance is $10.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL shares will trade within this expected range on the day.